Richard Jaenisch weighs how FDA's new NAM rule could reshape preclinical testing and what CMC teams should do now, on Manufacturing Intelligence.
|Articles|December 2, 2013
- Pharmaceutical Technology-12-02-2013
- Volume 37
- Issue 12
Rail-Mounted Fluid Bed Dryers Allow Cleaning Access
Author(s)Melanie Sena
Rail-Mounted Fluid Bed Dryers Allow Cleaning Access
Witte’s vibrating fluid bed dryers and coolers are available mounted on rails to allow unobstructed access for cleaning, maintenance, and visual inspection. During washdowns or for product changeovers, the drying and cooling sections spanning the complete length of the thermal processing system may be rolled out by one person and then rolled back into place without any tools. Specified for high-capacity fluidized bed dryers and coolers where access for inspection and cleaning are necessary, the rail-mounted vibratory dryers and coolers are designed for pharmaceuticals and other products that require dry processing. The steel rails include cushioned bumpers and are mounted into the floor during dryer installation.
Articles in this issue
almost 13 years ago
Biotechnology Innovation and Growth in Israelalmost 13 years ago
Drug Manufacturing Focus: Why India?almost 13 years ago
Clinical Trials Head East to Asiaalmost 13 years ago
Climate Change in Outsourcingalmost 13 years ago
Deficiencies Found in API Inspectionsalmost 13 years ago
Q&A with Brian Galliher, Cook Pharmicaalmost 13 years ago
Inspiring the Next Generationalmost 13 years ago
Establishing a Minimum Incubation Time for Biological Indicatorsalmost 13 years ago
Implementing QbD in Sterile ManufacturingRelated to this article
In a preview of their panel discussion at AAPS PharmSci 360 2026, Alfred Rumondor, PhD, AbbVie, and Swita Singh, PhD, Bristol Myers Squibb, discuss the implementation of risk-based approaches for CMC.
Ronald Piervincenzi, USP, urges drugmakers and purchasers to act on supply chain resilience to curb drug shortages and shape better policy.
Content on PharmTech.com this week ranged from fundamentals on the use of digital pathology in drug development, discussions on the use of AI in pharma, and regulatory actions impacting the industry.
Ronald Piervincenzi, USP, explains why manufacturers should act now and how benchmarking could reward reliable generic drug suppliers.
The FDA approves Lilly's once-weekly insulin efsitora for type 2 diabetes, raising Fc-fusion manufacturing, high-concentration pen, and capacity questions.
The agency issued a direct final rule that supports the use of innovative testing methods to limit the use of animals and maintain existing safety standards.
The FDA approves Inluriyo-Verzenio combo for ESR1-mutated breast cancer; EMBER-3 data double PFS, with supply chain and diagnostics implications for manufacturers.
Trending on Pharmaceutical Technology
1
Tavapadon Sets Development Benchmark for Parkinson's
2
KRAS G12D Inhibitor's $2.13B Deal Tests Cross-Border Tech Transfer
3
Weekly Basal Insulin Efsitora: A New Biologics CMC Benchmark
4
PharmTech’s Weekly Roundup—September 25, 2026
5